RxDoctor Payments Data

Sunil Patel, MD

Internal Medicine · Western Springs, ILNPI 1801987565

Payments from drug & device makers

$15,424in general payments, 2019–2025

Across 421 payments — averaging $36.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Adare Pharmaceuticals, Inc.$9K
  • Lilly USA, LLC$1K
  • GSK$826
  • Novo Nordisk$549
  • AstraZeneca$470
  • Boehringer Ingelheim$438
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$6,714100%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,424 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$14,188
Medicare patients
103
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$44,148
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$14,206
XareltoRivaroxaban13$10,911
Breo ElliptaFluticasone/Vilanterol18$10,742
EntrestoSacubitril/Valsartan11$7,815
Arnuity ElliptaFluticasone Furoate15$4,792
Atorvastatin Calcium245$3,034
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,303
Amlodipine Besylate296$2,043
Albuterol Sulfate HfaAlbuterol Sulfate62$1,885
Levothyroxine Sodium151$1,751
Metoprolol Succinate91$1,525
Gabapentin86$1,469
Rosuvastatin Calcium101$1,370
Pantoprazole Sodium65$1,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$427$44,14839 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$826$29,73945 claims
Johnson & JohnsonXarelto$62$10,91113 claims
NovartisEntresto$273$7,81511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Western Springs

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →